Neogenomics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021
May 05, 2021 at 03:03 pm IST
Share
NeoGenomics, Inc. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced total revenue was USD 115.533 million compared to USD 106.030 million a year ago. Operating loss was USD 15.107 million compared to USD 5.293 million a year ago. Net loss was USD 22.114 million compared to USD 6.978 million a year ago. Basic loss per share from continuing operations was USD 0.19 compared to USD 0.07 a year ago.
NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.